American Oncology Network (AONC) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 rose 39.8% year-over-year to $470.3M, driven by a 25.2% increase in patient encounters and higher revenue per encounter.

• Net loss attributable to Class A common stockholders was $2.5M for Q3 2024, an improvement from a $4.0M loss in Q3 2023.

• Adjusted EBITDA for Q3 2024 was $16.3M, up 30% year-over-year, reflecting core operating performance improvements.

• The company completed two acquisitions in Georgia and Hawaii, expanding its oncology network and contributing $64.9M in revenue since acquisition.

• A $51M equity financing was completed in November 2024 to support acquisitions and general corporate purposes.

Financial highlights

• Q3 2024 revenue: $470.3M, up from $336.3M in Q3 2023; nine-month revenue: $1.27B, up 32.8% year-over-year.

• Q3 2024 net loss attributable to AON Inc.: $1.1M; nine-month net loss: $5.3M.

• Q3 2024 basic and diluted loss per share: $(0.19); nine-month basic loss per share: $(0.90).

• Cost of revenue increased 39.5% year-over-year in Q3 2024, primarily due to higher drug and supply costs and increased patient volumes.

• Operating cash flow for the nine months ended September 30, 2024 was $(16.9)M, an increase in cash used compared to $(6.2)M in the prior year period.

Outlook and guidance

• Management expects continued revenue growth driven by organic expansion and further acquisitions.

• Cash on hand, recent equity financing, and available credit are expected to fund operations and capital needs for at least the next 12 months.

• The company is monitoring the financial impact of recent hurricanes but does not expect a material effect on operations.